WHO Updates Typhoid Conjugate Vaccine Guidance for India
The World Health Organization has released updated recommendations regarding the typhoid conjugate vaccine (TCV). Consequently, public health experts are urging swift national adoption to tackle India's alarming burden of drug-resistant enteric fever.
Alarming Typhoid Burden and Drug Resistance in India
Recent epidemiological modelling published in The Lancet Regional Health – Southeast Asia reveals an urgent crisis. In 2023 alone, India recorded approximately 4.9 million typhoid cases, 730,000 hospitalisations, and 7,850 deaths. Furthermore, fluoroquinolone-resistant strains caused nearly 82% of these hospital admissions. Children bear the brunt of this morbidity, with patients aged 5 to 14 years accounting for over 60% of treated cases. Additionally, infants and children aged 6 months to 4 years represent a quarter of infections and experience severe complications. Therefore, clinicians face severe limitations when prescribing first-line oral antimicrobials, forcing reliance on expensive injectable therapies.
WHO Recommendations on Typhoid Conjugate Vaccine Administration
To mitigate this escalating crisis, the WHO now advises routine administration of the typhoid conjugate vaccine in high-burden settings. Specifically, healthcare programmes should administer the primary dose to infants between 9 and 24 months of age. In addition, health authorities should implement catch-up vaccination campaigns covering children up to 15 years old. In regions with very high typhoid incidence, countries should evaluate a booster dose approximately five years after initial vaccination. However, policymakers must continuously review local surveillance data, antimicrobial resistance patterns, and cost-effectiveness before executing broad booster strategies.
Clinical Relevance and Integration into India's Universal Immunisation Programme
In India, the National Technical Advisory Group on Immunisation recommended incorporating TCV into the Universal Immunisation Programme in 2022. Expert scientists from the Indian Council of Medical Research emphasize that routine rollout is now vital. For instance, clinicians could administer the vaccine during the routine 18-month visit alongside the second measles-containing shot. Even without an immediate booster, a single dose confers robust immunological protection against circulating strains. Nevertheless, comprehensive enteric fever control also demands improvements in water sanitation, food hygiene, and rapid diagnostic testing.
Frequently Asked Questions
Q1: What is the recommended age for the primary typhoid conjugate vaccine dose?
The WHO recommends administering the primary dose between 9 and 24 months of age in areas with high disease incidence.
Q2: Why is the routine introduction of TCV critical in India?
Routine introduction is critical because over 80% of hospitalisations involve fluoroquinolone-resistant strains, severely restricting standard oral antibiotic treatments.
Q3: Is a booster dose necessary for children receiving TCV?
Countries with very high incidence should consider a booster dose around five years post-vaccination if surveillance indicates waning immunity.
For further professional upskilling, medical practitioners can explore specialized paediatrics speciality courses.
References
- WHO revises typhoid vaccine advice - ETHealthworld
- WHO position paper on typhoid vaccines, August 2026 - World Health Organization
- Burden of typhoid fever and antimicrobial resistance in India (2023): a modelling study - The Lancet Regional Health - Southeast Asia
